Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 16, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details specific transfers of Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- February 14, 2007: Transfer of 387,118 Ordinary Shares (advised on February 15, 2007).
- February 15, 2007: Transfer of 155,167 Ordinary Shares (advised on February 16, 2007).
Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the GSK Trust as potential beneficiaries alongside other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Total of 542,285 Ordinary Shares were transferred from the GSK Trust to employee plan participants between February 14 and February 15, 2007.
- The transactions were executed by Abacus (GSK) Trustees Limited as trustee of the GSK Trust.
- Three named directors have an indirect interest in the shares held within the GSK Trust.
- This filing does not contain financial performance data for the period.